Tag: Agenus (AGEN)
Prohost Letter #404 Part 2
Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of life. This is how Synthetic Genomics firm, which we believe is now is the leading biotech firm for applied synthetic biology. Synthetic Genomics is...
Read More
February 6, 2017
0
Agenus: Why Canceling Prophage Trial Should Not be Concerning
Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhibitors products and their checkpoint targets products are the talk...
Read More
February 22, 2017
0
Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued
The Diagnosed Dead Is Far from Dying Xoma (XOMA) : Stock rallied following report announcing an upfront payment from Novartis , which multiplied the firm’s revenues 10 times over 2014. Novartis paid Xoma $37 million, Novo Nordisk paid $5 million...
Read More
March 11, 2016
0
Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center
Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania . The aim of the agreement with Abramson Cancer Center at the University of Pennsylvania as Incyte (INCY) stated in the press release is...
Read More
February 24, 2017
0
Prohost Letter #393
Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer immunotherapy. We remind that in the Prohost...
Read More
March 4, 2016
0
Agenus Reform and Downsizing. Innoviva's Voting Dilemma
Agenus (AGEN ) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Among others are: - Closing its Basel site and...
Read More
March 30, 2017
0
Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL
Biotech N E W S AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has been dosed in Agenus (AGEN) Phase 1 clinical trial of its checkpoint inhibitor product AGEN1884. The open-label, multicenter trial in patients...
Read More
April 27, 2016
0
Prohost Letter #395
Prohost Letter #395 On the Road TO DEFEATING CANCER - Results of cancer treatment with novel immunotherapy drugs suggest that the hope of conquering cancer has improved from doubtful to conceivable. Immunotherapy treatments are scoring unprecedented successes against a wide...
Read More
May 4, 2016
0
Good News for Agenus and for Global Blood Therapeutics
Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration with Merck, which is known as MSD outside the United States and Canada. Merck has selected a lead antibody candidate and several backup antibodies,...
Read More
June 10, 2016
0
Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms
Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief Executive Pascal Soriot said that while DNA damage response was under-recognized by investors, oncologists were already “very excited” by its potential of the drugs...
Read More
May 16, 2016
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)